Evaluation of the response of breast cancer patients to neoadjuvant chemotherapy by combined contrast-enhanced ultrasonography and ultrasound elastography.

The purpose of the present study was to investigate whether contrast-enhanced ultrasonography (CEUS) in combination with ultrasound elastography (UE) is able to accurately predict the efficacy of neoadjuvant chemotherapy (NAC) in breast cancer patients. A total of 65 breast cancer patients who received NAC at the First Affiliated Hospital of Zhejiang University (Hangzhou, China) between February 2016 and August 2017 and were recruited for the present study. Prior to and after NAC, examination by CEUS, UE or their combination was performed. Pathological results were obtained at the end of each chemotherapy cycle, based on which 41 cases were assigned to the response group and 24 to the non-response group. Kappa values were 0.710, 0.434 and 0.836 for CEUS, UE and CEUS+UE, respectively. The area under the receiver operating characteristic curves for CEUS, UE and CEUS+UE for determining the response to NAC was 0.864 [95% confidence interval (CI), 0.765-0.964], 0.715 (95% CI, 0.579-0.850) and 0.910 (95% CI, 0.826-0.993), respectively. It was identified that the sensitivity, specificity, accuracy, positive predictive value and negative predictive value of CEUS+UE were higher than those of CEUS and US individually. The prediction accuracy was 89.2, 90.8 and 100% for CEUS, UE and their combination, respectively. CEUS and UE have their own advantages in evaluating the clinical efficacy of NAC in breast cancer, and a higher accuracy was achieved when the two techniques were applied in combination. Therefore, a combination of CEUS and UE may be a preferred method for the clinical assessment of the efficacy of NAC in breast cancer patients.

Introduction

ass="Disease">Breast cancer, a <ass="Gene">span class="Disease">malignant tumor type derived from the epithelium of terminal ductal lobules of the breast, is a disease that seriously threatens the health of women (1,2). An estimated 1.2 million women suffer from breast cancer worldwide, and 500,000 women die from the disease each year (3,4). In recent years, the incidence of breast cancer has increased in China (5,6). The development of methods for the precise diagnosis, selection of a suitable treatment and prediction of the outcome, as well as studies on the mechanism of carcinogenesis, have become major research topics in the field of breast cancer (7,8).

Neoadjuvant chemotherapy (ass="Chemical">NAC) is a systemic cytotoxic drug treatment method targeting the local <ass="Gene">span class="Disease">malignant tumor prior to surgery and/or radiotherapy. NAC has now become an important component of comprehensive breast cancer treatment (9). While a large number of clinical trials have proved that NAC is effective in treating advanced breast cancer, studies have also indicated that 10–35% of patients were insensitive to chemotherapy drugs. The effect of chemotherapy is not significant in those patients, which allows the disease to progress (10–12). Therefore, the effectiveness of NAC should be more precisely evaluated in order to provide breast cancer patients with an effective treatment plan.

Breast ultrasound is a low-cost and non-invasive imaging method, and due to its advantages of high resolution and ability to visualize impalpable lumps, it is superior to mammography, computed tomography (CT) and magnetic resonance imaging (MRI) (13–17). With the popularization of ultrasound and the rapid development of novel ultrasonic technology, high-frequency ultrasound, elastography and ultrasound contrast have been frequently applied to ass="Species">patients with suspected <ass="Gene">span class="Disease">breast cancer in the past years, which is helpful for improving the diagnostic accuracy (18–22). In the present study, contrast-enhanced ultrasonography (CEUS) and ultrasound elastography (UE) were used to evaluate the efficacy of NAC in breast cancer patients.

Patients and methods

Patients

A total of 65 ass="Disease">breast cancer <ass="Gene">span class="Species">patients who received NAC at the First Affiliated Hospital of Zhejiang University (Zhejiang, China) between February 2016 and August 2017 were recruited for the present study. All patients were confirmed via biopsy to have breast cancer prior to receiving NAC treatment and they received no other treatment. This study was approved by the ethics committee of the First Affiliated Hospital of Zhejiang University (Zhejiang, China). All patients provided written informed consent.

Chemotherapy regimen

Prior to surgery, all ass="Species">patients received 6 cycles of <ass="Gene">span class="Chemical">NAC with the ‘TEC’ chemotherapy regimen (docetaxel, 75 mg/m2; epirubicin, 75 mg/m2; cyclophosphamide, 500 mg/m2). Fluorescence in situ hybridization indicated that the tumors of 6 patients were positive for human epidermal growth factor receptor 2, and they were given the targeted drug herceptin (8 mg/kg body mass for the first time, followed by 6 mg/kg body mass). Drug treatment for 21 days was considered as 1 cycle and an interval of 20 days occurred following. Image examinations were performed prior to the next NAC cycle. Surgical excision was performed within 20 days after 6 cycles of drug treatment. A flow chart illustrating the chemotherapeutic regimen is presented in Fig. 1.

Figure 1.

Flow chart of NAC. Each cycle lasted for 21 days and surgical excision was performed within 20 days after 6 cycles. The parameters of CEUS and UE were recorded, including PI, AS, SR and SP. NAC, neoadjuvant chemotherapy; PI, peak intensity; AS, ascending slope; SR, strain ratio; SP, strain pressure; CEUS, contrast-enhanced ultrasonography; UE, ultrasound elastography.

CEUS examination

CEUS was performed using an ESAOTE MyLabClassC ultrasound diagnostic instrument (Esaote ass="Gene">SpA, Genoa, Spain). The ultrasound contrast agent SonoVue (59 µg; Bracco <ass="Gene">span class="Gene">SpA, Milan, Italy) was added to 5 ml saline and a milky microbubble suspension was generated by vigorous agitation. The largest section of the nodule was identified and its location was entered into a real-time ultrasound contrast model (QontraXt, Version 3.06). A total of 4.8 ml SonoVue suspension was rapidly injected through an anterior elbow vein and then 5 ml of saline was injected to flush the tube. The dynamic image at 180 sec was stored in real-time. Contrast observation continued until the lesion-enhanced image disappeared. The ultrasound contrast image was then processed, and the time-intensity curve was drawn for the region of interest (ROI). The parameters of CEUS including rise time (RT), time to peak (TTP), peak intensity (PI) and ascending slope (AS) were recorded. The differences in the parameters at the end of NAC vs. baseline (Δ) were calculated as follows: ΔAS=(AS0-AS6)/AS0×100% and ΔPI=(PI0-PI6)/PI0×100%, where AS0 and AS6 or the PI0 and PI6 are the AS or PI at baseline and after the 6th cycle of NAC, respectively.

UE examination

For UE, the ESAOTE MyLabClass C ultrasound diagnostic instrument was used (Esaote SpA, Genoa, Spain). First, conventional ultrasound scanning was implemented to locate the breast nodules, followed by switching to elastic mode, in which breast elastography was performed. The number of the pressure indicators of the display screen remained between 2 and 3, and the ROI remained 2–3 times larger than the nodule. UE observation was dynamically performed. According to the ‘5 Points Grading Method’ proposed by Itoh (23), the breast nodules were evaluated by elastic scoring, with 1–3 points indicating a benign, and 4 and 5 points suggesting a malignant status. The parameters of UE, including the strain ratio (SR) and strain point (SP), were recorded, and Δ values were calculated as follows: ΔSP=(SP0-SP6)/SP0×100%; ΔSR=(SR0-SR6)/SR0×100%.

The differential diagnosis was established by two senior physicians based on the results of CEUS and UE. To assess whether the <span class="Species">patient was responsive to <ass="Gene">span class="Chemical">NAC or not, the sensitivity, specificity and accuracy of CEUS, UE and the combination of the two were analyzed by comparison with the post-operative pathological diagnosis, which was considered as the gold standard.

CEUS and UE evaluation

According to the response evaluation criteria in ass="Disease">solid tumors (24), changes in the longest diameter of the lesion prior to and after chemotherapy were compared. A total reduction of the maximum diameter of the lesion of ≥30%, or disappearance of the lesion with no new lesion appearing, was defined as a ‘response’ to <ass="Gene">span class="Chemical">NAC. A ‘non-response’ was defined as the longest diameter of the original lesion being decreased by <30% or increased after NAC, or the appearance of a new focus.

Pathological evaluation

According to the ass="Disease">tumor response grade proposed by Eisenhauer et al (25), the histopathology results of the lesion samples isolated in the surgery were compared with those of the biopsy specimens obtained prior to treatment to determine the response to <ass="Gene">span class="Chemical">NAC, based on which the patients were stratified into two groups: A reduction in the relative number of cancer cells by <30% was defined as ‘non-response’, while a ‘response’ was considered when cancer cells were reduced by ≥30%.

Statistical analysis

The data were analyzed by SPSS version 20 statistics software (IBM Corp., Armonk, NY, USA). The Chi square test was used for evaluation of count data. The Kappa test was performed to analyze the results of CEUS and UE to evaluate the outcome of <span class="Chemical">NAC as well as the consistency with the results of the post-operative pathological evaluation. Parameter changes of CEUS and UE were assessed by Student's t-test. The prediction rate was calculated using univariate logistic regression analysis. Receiver operating characteristic (ROC) curves and the area under the curve (AUC) were obtained for CEUS and UE to evaluate <ass="Gene">span class="Chemical">NAC efficacy. P<0.05 was considered to indicate a statistically significant difference.

Results

Characteristics of the patients and their tumors

The baseline characteristics of the ass="Species">patients are presented in Table I. No significant differences in the clinicopathological characteristics at baseline were identified between the response and no response groups. Post-operative histopathological analysis indicated that the density of <ass="Gene">span class="Disease">cancers cells was relatively high in the tumors from non-response patients, while it was relatively low in the response patients (Fig. 2A and B). Invasive ductal carcinoma of the breast was confirmed through tissue coarse needle biopsy prior to NAC (Fig. 2C). After NAC, the surgical specimen was confirmed as grade 4 (Fig. 2D).

Table I.

Clinicopathological features of the patients at baseline.

Characteristic	Response group (n=41)	No response group (n=24)	P-value
Age (years)	48.3±5.7	50.2±4.9	0.170
Menopausal status			0.608
Pre-menopause	21 (51.21%)	10 (41.67%)
Post-menopause	20 (18.79%)	14 (58.33%)
Tumor size (cm)			1.000
>4	10 (24.39%)	5 (20.83%)
<4	31 (75.61%)	19 (79.17%)
Histological grade			1.000
2	25 (60.98%)	15 (62.50%)
3	16 (39.02%)	9 (37.50%)
Tumor subtype			0.601
Luminal A	14 (34.15%)	10 (41.67%)
Luminal B	27 (65.85%)	14 (58.33%)
Nodal status			0.785
Negative	29 (70.73%)	16 (66.67%)
Positive	12 (29.27%)	8 (33.33%)

Values are expressed as the mean ± standard deviation or n (%).

Figure 2.

Histopathological identification of patient responses with H&E staining. Representative H&E staining of histology images of patients in (A) the non-response group and (B) the response group (magnification in left panel, ×100; the right panel shows the windows from the left panel at a magnification of ×400). (C) Representative H&E staining of tissue coarse needle biopsy from one patient in the response group was performed and invasive ductal carcinoma of the breast was confirmed prior to NAC. (D) Following NAC, H&E staining of the surgical specimen of this patient was confirmed as grade 4 (magnification, ×100). NAC, neoadjuvant chemotherapy.

Performance of CEUS and UE in evaluating the efficiency of NAC

The Kappa test was used to analyze the consistency of the evaluation results of CEUS, US and their combination with the results of the post-operative pathological evaluation. The pathological results indicated that 41 cases exhibited a response to <span class="Chemical">NAC and 24 cases did not (Table II). A Kappa value of >0.75 indicated good consistency, 0.75>Kappa>0.4 suggested moderate consistency and Kappa <0.4 was considered to indicate poor consistency. This suggested that combination of CEUS and UE have a good efficiency in predicting the response to NAS based on histopathological examinations. CEUS was also demonstrated to do this more efficiently than UE. In addition, the sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) of CEUS and UE were analyzed. The AUC of the ROC for the prediction of a response by CEUS was 0.864 [95% confidence interval (CI), 0.765–0.964]. Furthermore, the AUC for UE was 0.715 (95% CI, 0.579–0.850) and that of CEUS+UE was 0.910 (95% CI, 0.826–0.0.993; Fig. 3). The sensitivity, specificity, accuracy, PPV and NPV of CUES and of UE are presented in Table III. It was observed that the AUC, sensitivity, specificity, accuracy and PPV of CEUS+UE were higher than those of CEUS or UE alone.

Table II.

Comparison of evaluation of CEUS and UE with pathological evaluation.

		Histology
Imaging modality/result	Total n (%)	Response	No response	Kappa	P-value
CEUS
Response	38 (58.46%)	35 (85.37%)	3 (14.29%)	0.710	<0.001
No response	27 (41.54%)	6 (14.63%)	21 (85.71%)
Total	65	41	24
UE
Response	42 (64.62%)	33 (80.49%)	9 (37.50%)	0.434	<0.001
No response	23 (35.38%)	8 (19.51%)	15 (62.50%)
Total	65	41	24
CEUS+UE
Response	40 (61.54%)	38 (92.68%)	2 (4.88%)	0.836	<0.001
No response	25 (38.45%)	3 (7.32%)	22 (95.12%)
Total	65	41	24

CEUS, contrast-enhanced ultrasonography; UE, ultrasound elastography.

Figure 3.

ROC analysis for CEUS, UE and their combination in the prediction of the response to NAC in breast cancer patients. CI, confidence interval; AUC, area under the ROC curve; ROC, receiver operating characteristic; CEUS, contrast-enhanced ultrasonography; UE, ultrasound elastography.

Table III.

Comparison of sensitivity, specificity, accuracy, PPV and NPV (%) between CEUS, UE and their combination.

Parameter	CEUS	UE	CEUS+UE
Sensitivity	85.36	80.49	92.68
Specificity	87.50	62.50	91.67
Accuracy	86.15	73.85	92.31
PPV	92.11	78.57	95.00
NPV	77.77	65.22	87.99

PPV, positive predictive value; NPV, negative predictive value; CEUS, contrast-enhanced ultrasonography; UE, ultrasound elastography.

Image and parameter analysis of CEUS and UE

The CEUS images were analyzed using Philips QLAB ultrasound contrast quantitative analysis software (Fig. 4). The maximum signal intensity in the non-response group was identified to be stronger than that in the response group (Fig. 4). The corresponding time-signal intensity curve in the response group was more stable than that in the non-response group (Fig. 4B and D). Subsequently, the parameters of CEUS obtained from the images were analyzed. In comparison with those in the non-response group, the PI and ascending slope AS were significantly reduced in the response group, while the RT and TTP remained relatively stable. Furthermore, it was identified that compared with the baseline values, the PI and AS were obviously decreased after <span class="Chemical">NAC in the non-response and response groups (Table IV).

Figure 4.

Representative CEUS images of non-response/response patients. (A) CEUS image and (B) time-Si curve for a non-response patient. (C) CEUS image and (D) time-Si curve for a patient with response to neo-adjuvant chemotherapy. Areas gated with red lines represent the region of interest. CEUS, contrast-enhanced ultrasonography; Si, signal intensity; ms, milliseconds.

Table IV.

Quantitative parameters of CEUS prior to and after NAC.

Parameter/time-point	Response (n=41)	No response (n=24)	P-value
RT after NAC	9.43±2.61	8.25±2.67	0.086
TTP after NAC	19.05±4.17	21.10±4.37	0.065
PI
Prior to NAC	26.18±3.82	25.32±4.11	0.398
After NAC	13.87±3.77[a]	22.34±4.05[b]	<0.001
AS
Prior to NAC	1.65±0.50	1.41±0.42	0.052
After NAC	0.78±0.29[a]	1.06±0.24[a]	<0.001

P≤0.001

P<0.05 vs. prior to NAC. CEUS, contrast-enhanced ultrasonography; NAC, neoadjuvant chemotherapy; PI, peak intensity; TTP, time to peak; PI, peak intensity; AS, ascending slope.

CEUS and UE imaging was performed prior to the next ass="Chemical">NAC cycle, and prior to the operation. The images revealed that compared with the non-response group, the residual <ass="Gene">span class="Disease">tumor in the response group was markedly reduced (Fig. 5). Subsequently, the parameters of UE were determined based on the images. The results indicated that the percentage of cases with 1–3 points according to the ‘5 Points Grading Method’ in the response group was higher than that in the non-response group. However, the percentage of cases with 4 or 5 points in the response group was lower than that in the non-response group (Table V). Furthermore, the strain ratio (SR) after NAC was conspicuously reduced in the response group compared with that the non-response group (2.11±0.52 vs. 3.71±1.29), whereas no differences were observed prior to NAC between them. In addition, in comparison with the baseline, the number of the cases with 1–3 points was significantly increased, while the SR and the number of the cases with 4 and 5 points were markedly decreased in either group after NAC (Table V).

Figure 5.

Representative images of CEUS and UE. CEUS and UE images of (A) a non-response patient and (B) a response patient obtained prior to the next NAC cycle and during the pre-operative diagnosis. CEUS, contrast-enhanced ultrasonography; UE, ultrasound elastography; W8, week 8; Pre-tr, pre-treatment; Pre-Op, pre-operative.

Table V.

Comparison of points of UE evaluated using the ‘5 Point Grading Method’ (23) prior to and following NAC.

	Response (n=41)			No response (n=24)
Time-point	1–3 points	4/5 points	SR	1–3 points	4/5 points	SR
Prior to NAC	10	31	6.70±1.46	5	19	5.89±1.33
After NAC	34	7	2.11±0.52	14	10	3.71±1.29[a]
P-value	<0.001		<0.001	0.008		<0.001

UE, ultrasound elastography; NAC, neoadjuvant chemotherapy; SR, strain ratio

P<0.0001 vs. the response for SR.

Accuracy of CEUS and UE in predicting the efficiency of NAC

ROC curves, the optimal cutoff and the area under the ROC (AUC) were obtained for the parameters of CEUS and UE, namely ΔAS, ΔPI, ΔSP and ΔSR (Fig. 6). The optimal cutoff values for ΔAS, ΔPI, ΔSP and ΔSR were >36.94, 21.15, 40 and 52.50%, respectively. ROC curve analysis for ΔAS indicated that the sensitivity, specificity, accuracy, PPV and NPV were 87.80, 95.83, 90.76, 97.29 and 82.14%, respectively, while they were 90.24, 95.83, 92.30, 97.37 and 85.18% for ΔPI. Furthermore, the sensitivity, specificity, accuracy, PPV and NPV for ΔSP and ΔSR were 65.85 and 92.68%, 83.33 and 87.50%, 72.30 and 90.76%, 87.09 and 92.68%, and 58.82 and 87.50%, respectively (Table VI). The prediction accuracy rates of CEUS, UE and CEUS+UE were determined by a combination of ΔPI, ΔAS, ΔSP or ΔSR using logistics analysis (Table VII). The CEUS prediction rate with ΔPI and ΔAS as the influence factors was 89.2%, whereas the UE prediction rate with ΔSP and ΔSR as the influence factors was 90.8%. The combination prediction rate of CEUS+UE with ΔSP, ΔSR and ΔPI as the influence factors was 100%.

Figure 6.

Analysis of the ROC curves of CEUS and UE in the prediction of the response to NAC in breast cancer patients. The receiver operating characteristics curves of ΔAS, ΔPI, ΔSP and ΔSR for prediction of the response to NAC. AUC, area under the ROC curve; ROC, receiver operating characteristic; Δ, difference between baseline and 6 cycles of NAC; AS, ascending slope; PI, peak intensity; SP, strain point; SR, strain ratio; NAC, neoadjuvant chemotherapy.

Table VI.

Sensitivity, specificity, accuracy, PPV and NPV of CEUS and UE in the prediction of response to neoadjuvant chemotherapy (%).

	CEUS		UE
Parameter	ΔAS	ΔPI	ΔSP	ΔSR
Sensitivity	87.80	90.24	65.85	92.68
Specificity	95.83	95.83	83.33	87.50
Accuracy	90.76	92.30	72.30	90.76
PPV	97.29	97.37	87.09	92.68
NPV	82.14	85.18	58.82	87.50

PPV, positive predictive value; NPV, negative predictive value; CEUS, contrast-enhanced ultrasonography; UE, ultrasound elastography; Δ, difference between baseline and 6 cycles of NAC; AS, ascending slope; PI, peak intensity; SP, strain point; SR, strain ratio.

Table VII.

Prediction rate of CEUS and UE according to univariate logistic regression analysis[a].

Modality/parameter	β	P-value	OR (95% CI)
CEUS
ΔPI	−0.102	0.084	0.903 (0.804–1.014)
ΔAS	−0.094	0.179	0.910 (0.793–1.044)
Constant	8.636	0.001	–
UE
ΔSP	0.067	0.010	1.069 (1.016–1.125)
ΔSR	0.144	<0.001	1.155 (1.074–1.242)
Constant	−9.964	<0.001	–
CEUS+UE
ΔSP	0.786	0.996	2.194
ΔSR	1.218	0.993	3.380
ΔPI	−2.058	0.993	0.128
Constant	−12.628	0.999	–

The P-value of ΔAS (0.179) was >0.1 and as such was not included in the combination analysis (CEUS+UE). CEUS, contrast-enhanced ultrasonography; UE, ultrasound elastography; Δ, difference between baseline and 6 cycles of NAC; AS, ascending slope; PI, peak intensity; SP, strain point; SR, strain ratio; PI, peak intensity; CI, confidence interval; OR, odds ratio; constant, constant of the logistic regression equation.

Logistics regression model: (for CEUS, β0: Constant; ΔPI: β1; ΔAS: β2. for UE, β0: Constant; ΔSP: β1; ΔSR: β2. for CEUS+UE, β0: Constant; ΔSP: β1; ΔSR: β2; ΔPI: β3).

Discussion

Since the 1970s, ass="Chemical">NAC has been a critical part of the comprehensive treatment of <ass="Gene">span class="Disease">breast cancer. NAC may reduce tumor cells and significantly increase the rate of breast-conserving and surgical resection (26,27). Pathological examination is a gold standard for evaluating tumor response after a patient received NAC and it has a high diagnostic accuracy. However, in addition to the post-operative examination, the efficiency of NAC should ideally be determined at the end of/during NAC, as the pre-operative prediction of the pathological response to NAC allows for individualized breast cancer surgery timing (28,29). Therefore, recent studies have encouraged the use of repeated, non-invasive monitoring by imaging examinations so as to evaluate the efficacy of NAC (17,30,31).

Imaging evaluation of the response of ass="Disease">breast cancer to <ass="Gene">span class="Chemical">NAC is required to be performed from two aspects of qualitative and quantitative data. While a unified assessment system is currently lacking, the evaluation standard regarding the size of the lesion is unified. The standard is to compare the longest diameter in images prior to and after NAC and to thereby evaluate the response. After NAC, the regression of tumor cells mainly manifests as necrosis and fibrosis of the lesions (32,33). Conventional ultrasound cannot accurately distinguish between necrosis, fibrous hyperplasia and residual cancer (34).

ass="Disease">Breast cancer is a vasculature-derived disease and with abundant neovascularization. The formation of neovascularization is critically associated with the prognosis of <ass="Gene">span class="Species">patients with breast cancer (35,36). CEUS is able to detect microvessels of <40 µm in diameter and to clearly display the shape and distribution of the lesion, as well as the blood vessels (31,37). CEUS has proven effective in evaluating the clinical response of various cancer types to NAC (14,30,38,39). In the present study, CEUS was identified to have a good performance in evaluating the effect of NAC. The parameters of PI and AS were significantly decreased in the responsive patients compared to those in the patients that were unresponsive to NAC. Furthermore, in comparison with the baseline, the PI and AS were also markedly reduced after NAC in the response and non-response groups after NAC. CEUS predicted the effectiveness of NAC with the rate of correct prediction of the response to NAC being 89.2%. The above results proved that CEUS may be used to efficiently predict the pathological response of breast tumors to NAC.

UE is able to reflect the elastic characteristics of various biological tissues, and may provide useful clues for diagnosing ass="Disease">breast diseases; therefore, it is regarded as a beneficial supplementary method to conventional ultrasound (19). The most commonly used UE techniques are elastic scoring and the SR method (40,41). Previous studies have indicated that by combination of the two-dimensional grayscale image and the elastic scoring method, a high accuracy in the diagnosis of benign and malignant breast nodules was achieved (40). Hence, in the present study, the methods of elastic scoring and SR were also selected so as to explore the aptness of UE for evaluation of the efficacy of <ass="Gene">span class="Chemical">NAC. The rate of correct prediction of the response to NAC of UE with ΔSP and ΔSR as influence factors was 90.8%. These results suggested that UE may be used to assess the pathological response of breast tumors to NAC.

To the best of our knowledge, no previous study has evaluated the combined use of CEUS and UE for evaluation of the efficacy of ass="Chemical">NAC for <ass="Gene">span class="Disease">breast cancer. It was hypothesized that CEUS in combination with UE may predict NAC more accurately than CEUS alone. As expected, the predictive accuracy of the combined evaluation by CEUS or UE was higher than that of each imaging modality implemented individually. When CEUS was combined with UE, the sensitivity, specificity, accuracy, PPV and NPV were identified to be higher than those of CEUS or UE applied individually. Furthermore, the predictive accuracy rate of combined CEUS and UE was 100%, proving that CEUS in combination with UE was highly accurate in evaluating the efficacy of NAC for breast cancer.

The present clinical study demonstrated that CEUS and UE have their individual advantages in evaluating the clinical efficacy of ass="Chemical">NAC for <ass="Gene">span class="Disease">breast cancer, and that the combination of the two was more accurate. It is therefore recommended that this combined method is widely implemented in the clinical assessment of the efficacy of NAC for breast cancer patients. The present study is of great clinical significance and paves the road for further in-depth research on the combined use of CEUS and UE so as to predict the pathological response of breast cancer after patients have received NAC.